|
1
|
Gilliland DG and Tallman MS: Focus on
acute leukemias. Cancer Cell. 1:417–420. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huang ME, Ye YC, Chen SR, Zhao JC, Gu LJ,
Cai JR, Zhao L, Xie JX, Shen ZX and Wang ZY: All-trans retinoic
acid with or without low dose cytosine arabinoside in acute
promyelocytic leukemia. Report of 6 cases. Chin Med J. 100:949–953.
1987.
|
|
3
|
Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J,
Cai X, Han ZG, Ni JH, Shi GY, Jia PM, et al: Use of arsenic
trioxide (As2O3) in the treatment of acute
promyelocytic leukemia (APL): I. As2O3 exerts
dose-dependent dual effects on APL cells. Blood. 89:3345–3353.
1997.PubMed/NCBI
|
|
4
|
Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM,
Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, et al: Use of arsenic
trioxide (As2O3) in the treatment of acute
promyelocytic leukemia (APL): II. Clinical efficacy and
pharmacokinetics in relapsed patients. Blood. 89:3354–3360.
1997.
|
|
5
|
Dombret H, Castaigne S, Fenaux P,
Chomienne C and Degos L: Induction treatment of acute promyelocytic
leukemia using all-trans retinoic acid. Controversies about dosage,
advantages and side-effect management. Leukemia. 8:(Suppl 3).
S73–S75. 1994.PubMed/NCBI
|
|
6
|
Tomita A, Kiyoi H and Naoe T: Mechanisms
of action and resistance to all-trans retinoic acid (ATRA) and
arsenic trioxide (As2O3) in acute
promyelocytic leukemia. Int J Hematol. 97:717–725. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kosugi H, Towatari M, Hatano S, Kitamura
K, Kiyoi H, Kinoshita T, Tanimoto M, Murate T, Kawashima K, Saito
H, et al: Histone deacetylase inhibitors are the potent
inducer/enhancer of differentiation in acute myeloid leukemia: A
new approach to anti-leukemia therapy. Leukemia. 13:1316–1324.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kuendgen A, Strupp C, Aivado M, Bernhardt
A, Hildebrandt B, Haas R, Germing U and Gattermann N: Treatment of
myelodysplastic syndromes with valproic acid alone or in
combination with all-trans retinoic acid. Blood. 104:1266–1269.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Raffoux E, Chaibi P, Dombret H and Degos
L: Valproic acid and all-trans retinoic acid for the treatment of
elderly patients with acute myeloid leukemia. Haematologica.
90:986–988. 2005.PubMed/NCBI
|
|
10
|
Kuendgen A, Knipp S, Fox F, Strupp C,
Hildebrandt B, Steidl C, Germing U, Haas R and Gattermann N:
Results of a phase 2 study of valproic acid alone or in combination
with all-trans retinoic acid in 75 patients with myelodysplastic
syndrome and relapsed or refractory acute myeloid leukemia. Ann
Hematol. 84:(Suppl 1). S61–S66. 2005. View Article : Google Scholar
|
|
11
|
Kuendgen A, Schmid M, Schlenk R, Knipp S,
Hildebrandt B, Steidl C, Germing U, Haas R, Dohner H and Gattermann
N: The histone deacetylase (HDAC) inhibitor valproic acid as
monotherapy or in combination with all-trans retinoic acid in
patients with acute myeloid leukemia. Cancer. 106:112–119. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fredly H, Gjertsen BT and Bruserud O:
Histone deacetylase inhibition in the treatment of acute myeloid
leukemia: The effects of valproic acid on leukemic cells, and the
clinical and experimental evidence for combining valproic acid with
other antileukemic agents. Clin Epigenetics. 5:122013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tassara M, Döhner K, Brossart P, Held G,
Götze K, Horst HA, Ringhoffer M, Köhne CH, Kremers S, Raghavachar
A, et al: Valproic acid in combination with all-trans retinoic acid
and intensive therapy for acute myeloid leukemia in older patients.
Blood. 123:4027–4036. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zapotocky M, Mejstrikova E, Smetana K,
Stary J, Trka J and Starkova J: Valproic acid triggers
differentiation and apoptosis in AML1/ETO-positive leukemic cells
specifically. Cancer Lett. 319:144–153. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Leiva M, Moretti S, Soilihi H, Pallavicini
I, Peres L, Mercurio C, Dal Zuffo R, Minucci S and de Thé H:
Valproic acid induces differentiation and transient tumor
regression, but spares leukemia-initiating activity in mouse models
of APL. Leukemia. 26:1630–1637. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Iriyama N, Yuan B, Yoshino Y, Hatta Y,
Horikoshi A, Aizawa S, Takei M, Takeuchi J, Takagi N and Toyoda H:
Enhancement of differentiation induction and upregulation of
CCAAT/enhancer-binding proteins and PU.1 in NB4 cells treated with
combination of ATRA and valproic acid. Int J Oncol. 44:865–873.
2014.PubMed/NCBI
|
|
17
|
Heo SK, Noh EK, Yoon DJ, Jo JC, Park JH
and Kim H: Dasatinib accelerates valproic acid-induced acute
myeloid leukemia cell death by regulation of differentiation
capacity. PLoS One. 9:e988592014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Armeanu S, Bitzer M, Lauer UM, Venturelli
S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, et
al: Natural killer cell-mediated lysis of hepatoma cells via
specific induction of NKG2D ligands by the histone deacetylase
inhibitor sodium valproate. Cancer Res. 65:6321–6329. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang C, Wang Y, Zhou Z, Zhang J and Tian
Z: Sodium butyrate upregulates expression of NKG2D ligand MICA/B in
HeLa and HepG2 cell lines and increases their susceptibility to NK
lysis. Cancer Immunol Immunother. 58:1275–1285. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu X, Ohata K, Kondo Y, Espinoza JL, Qi Z
and Nakao S: Hydroxyurea upregulates NKG2D ligand expression in
myeloid leukemia cells synergistically with valproic acid and
potentially enhances susceptibility of leukemic cells to natural
killer cell-mediated cytolysis. Cancer Sci. 101:609–615. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Poggi A, Catellani S, Garuti A, Pierri I,
Gobbi M and Zocchi MR: Effective in vivo induction of NKG2D ligands
in acute myeloid leukaemias by all-trans-retinoic acid or sodium
valproate. Leukemia. 23:641–648. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Phiel CJ, Zhang F, Huang EY, Guenther MG,
Lazar MA and Klein PS: Histone deacetylase is a direct target of
valproic acid, a potent anticonvulsant, mood stabilizer, and
teratogen. J Biol Chem. 276:36734–36741. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Johannessen CU and Johannessen SI:
Valproate: Past, present, and future. CNS Drug Rev. 9:199–216.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Göttlicher M, Minucci S, Zhu P, Krämer OH,
Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG,
et al: Valproic acid defines a novel class of HDAC inhibitors
inducing differentiation of transformed cells. EMBO J.
20:6969–6978. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu S, Klisovic RB, Vukosavljevic T, Yu J,
Paschka P, Huynh L, Pang J, Neviani P, Liu Z, Blum W, et al:
Targeting AML1/ETO-histone deacetylase repressor complex: A novel
mechanism for valproic acid-mediated gene expression and cellular
differentiation in AML1/ETO-positive acute myeloid leukemia cells.
J Pharmacol Exp Ther. 321:953–960. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cheng YC, Lin H, Huang MJ, Chow JM, Lin S
and Liu HE: Downregulation of c-Myc is critical for valproic
acid-induced growth arrest and myeloid differentiation of acute
myeloid leukemia. Leuk Res. 31:1403–1411. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Deubzer H, Busche B, Rönndahl G, Eikel D,
Michaelis M, Cinatl J, Schulze S, Nau H and Witt O: Novel valproic
acid derivatives with potent differentiation-inducing activity in
myeloid leukemia cells. Leuk Res. 30:1167–1175. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bartolini G, Orlandi M, Papi A, Ammar K,
Tonelli R, Franzoni M, Pession A, Rocchi P and Ferreri AM: Growth
inhibition and proapoptotic activity induction by IIF and valproic
acid on RA-resistant leukemia cells. Anticancer Res. 28:283–288.
2008.PubMed/NCBI
|
|
29
|
Vrba J, Dolezel P and Ulrichova J:
Neutrophilic differentiation modulates the apoptotic response of
HL-60 cells to sodium butyrate and sodium valproate. Neoplasma.
57:438–448. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Diermayr S, Himmelreich H, Durovic B,
Mathys-Schneeberger A, Siegler U, Langenkamp U, Hofsteenge J,
Gratwohl A, Tichelli A, Paluszewska M, et al: NKG2D ligand
expression in AML increases in response to HDAC inhibitor valproic
acid and contributes to allorecognition by NK-cell lines with
single KIR-HLA class I specificities. Blood. 111:1428–1436. 2008.
View Article : Google Scholar : PubMed/NCBI
|
